Skip to content
Head to head

Beam Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: BEAM · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

BEAM -5.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
BEAMVRTX
Snapshot
Sector--Biotechnology
Last price20.90515.02
Change today-0.19%-1.08%
1-year return+1.5%+22.0%
Market cap$2.16B$130.58B
52-week range20.44 – 38.26412.27 – 568.67
Valuation
P/E (TTM)-23.7533.14
P/E percentile, own 5-yr range15th99th
P/B2.276.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.8115.32
Net profit (TTM)$-83.83M$3.88B
Revenue (TTM)$146.64M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-96.8%+11.8%
Gross margin--85.5%
Operating margin-267.7%33.1%
Net margin-73.9%30.7%
Free cash flow (TTM)$-398.24M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership114.0%96.8%
Insider activity (12mo)19 buy / 31 sell28 buy / 22 sell
Short interest (% of float)25.3%1.9%
Analyst consensus92% buy / 8% hold (12)95% buy / 5% hold (21)
Analyst price target$49 (+136%)$624 (+21%)
StockVane view
StockVane Quant RatingD (39)C (68)
Company
Employees5116,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.